• Lucie Hromadkova, Tomas Soukup, and Jiri Vlcek.
• Department of Clinical Pharmacy, Hospital Na Homolce, Prague, Czech Republic.
• J Eval Clin Pract. 2015 Oct 1; 21 (5): 919-24.

Rationale, Aims And ObjectivesIn rheumatic disorders, one of the treatment objectives is to improve the patient's quality of life (QoL). Similar to other chronic conditions, drug compliance is poor, but necessary for successful treatment. The relationship between drug compliance and QoL has never been tested. The aim of this study was to elucidate the relationship between drug compliance and QoL in patients with different rheumatic disorders.MethodA cross-sectional study was conducted and patients ≥18 years of age with rheumatoid arthritis (RA), spondyloarthritis (SA), juvenile idiopathic arthritis (JIA) and systemic scleroderma (SSc) were recruited. Data were collected by questionnaires including the Short Form 36 version 2, Compliance Questionnaire Rheumatology (CQR), Health Assessment Questionnaire and by a general questionnaire that focused on demographic characteristics.ResultsThe questionnaires were completed by 289 patients. Of the respondents, 61.6% (178) were treated for RA, 16.3% (47) for SA, 14.2% (41) for SSc and 8% (23) for JIA. The median of CQR score ranged from 66.7 (JIA) to 82.5 (RA), with 51.6% of patients reaching a score <80. QoL was decreased mainly in the physical component, with the lowest rate for patients with SSc. Higher compliance was observed in patients with decreased QoL (physical component), nevertheless, statistical significance of the relationship was reached only in JIA and SA patients.ConclusionDoctors caring for rheumatic patients should focus their efforts on strengthening drug compliance in patients with higher QoL where it seems that lower compliance is more likely.© 2015 John Wiley & Sons, Ltd.

33 keywords...

hide…